 Home > Biochemistry News > Biotechnology News > CRISPR-edited stem cell therapy for the treatment of acute myeloid leukemia obtains FDA fast-track qualification

CRISPR-edited stem cell therapy for the treatment of acute myeloid leukemia obtains FDA fast-track qualification

 Last Update: 2021-09-19
 Source: Internet
 Author: User

Tags

casein protein side effects

what's healthy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 9, Vor Biopharma announced that the U.
S.
FDA has granted its engineered hematopoietic stem cell (eHSC) candidate drug VOR33 fast track qualification for the treatment of acute myeloid leukemia (AML)
.

In AML patients, CD33 protein is expressed on the surface of tumor cells in large quantities
.

Targeted therapies targeting CD33 may cause toxic side effects due to the combination of CD33 expressed on the surface of healthy cells and "injury" to healthy cells

Therefore, the hematopoietic stem cells infused back into the patient will produce healthy new cells that do not express CD33 protein
.

Healthy cells are like wearing a "invisibility cloak" and will not be accidentally injured by drugs

▲The working mechanism of the eHSC platform (picture source: Vor official website)

Note: The original text has been deleted

Reference materials:

[1] VOR33 Granted US FDA Fast Track Designation for AML.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express treatment of acute myeloid leukemia, CRISPR-edited stem cell therapy obtained FDA fast track qualification

10-02

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

CRISPR-edited stem cell therapy for the treatment of acute myeloid leukemia obtains FDA fast-track qualification

Related Articles

Express treatment of acute myeloid leukemia, CRISPR-edited stem cell therapy obtained FDA fast track qualification